The 340B environment has continued to evolve, and this year has been particularly busy as the drug pricing program is targeted and challenged. Covered Entities (CEs) and other professionals are invited to join us for an update on federal and state regulatory and legislative activity along with a discussion on the administrative dispute resolution process, Medicare Advantage payer litigation, and how CEs can continue to maintain a compliant 340B program despite these challenges.
Attendees learned more about the latest challenges to the 340B drug pricing program and how you can maintain a compliant program during this webinar which took place on October 23, 2024.
During this webinar, PYA’s Sarah Bowman discussed key updates to 340B as attendees learned from these objectives:
- Discussed key state and federal legislative activity
- Provided a regulatory update
- Reviewed the status of drug manufacturer restrictions and the Administrative Dispute Resolution process
- Described Medicare Advantage payer litigation activity
- Discussed HRSA Audit activity and Covered Entity best practices
RESOURCES:
This webinar was part of PYA’s twice-monthly Healthcare Regulatory Roundup, a popular series during which PYA experts provide practical insights on the latest industry regulatory developments.
If you would like assistance with legislative or regulatory impacts or any matter involving compliance, valuation, or strategy and transactions, our executives are happy to assist.
